A small Mediterranean island, a centuries-old disease, and a quiet genetic twist in human blood cells are reshaping medical hopes.
New research on Sardinian volunteers has pinpointed a rare gene variant in red blood cells that weakens malaria’s deadliest parasite, opening a fresh front in the search for more durable treatments.
A genetic shield forged by centuries of malaria
Malaria still hits hard: more than 200 million infections and over 600,000 deaths every year, mostly in sub-Saharan Africa. For thousands of years, populations exposed to the disease have been under relentless evolutionary pressure. In some places, human DNA quietly adapted.
Sardinia, off the coast of Italy, was one of Europe’s malaria hotspots until the 1950s. Before large-scale eradication campaigns, entire generations grew up under constant risk of Plasmodium falciparum infection, the species responsible for most severe and fatal cases.
That history left genetic fingerprints. A team led by Francesco Cucca at the University of Sassari and the National Research Council in Cagliari analysed the genomes of nearly 7,000 Sardinians as part of the long-running SardiNIA project. They matched genetic data with precise blood measurements.
The researchers identified a rare variant in the CCND3 gene that appears to blunt the parasite’s ability to reproduce inside red blood cells.
This variant, known as rs112233623-T, showed up in roughly 10% of the Sardinians studied. Outside the island, it is far less frequent, almost vanishing in many European populations. Statistical signals suggest natural selection boosted its presence in Sardinia during the centuries when malaria circulated intensely.
How a tweak in CCND3 reshapes red blood cells
CCND3 encodes cyclin D3, a protein that helps control the cell cycle. In the bone marrow, it governs how many times immature red blood cell precursors divide before maturing. This process sets both the final size and number of red blood cells circulating in the bloodstream.
In people carrying the Sardinian CCND3 variant, gene activity drops slightly. Their red blood cell precursors divide fewer times. That subtle change shifts the outcome: they produce red blood cells that are a bit larger and altered in quantity, though still compatible with normal health.
When scientists examined these modified cells in the lab, something striking emerged. Levels of oxidative stress inside the cells were higher. In other words, the red blood cells contained more reactive oxygen species, chemically active molecules that can damage cellular components.
➡️ Four men in unredacted files named by Ro Khanna have no ties to Epstein | Jeffrey Epstein
➡️ A mouse study suggests strength training may beat running for diabetes prevention
➡️ Psychology: the chair you choose to sit on reveals what kind of person you are at work
➡️ For the first time in 40 years, Panama’s deep waters did not rise to the surface
➡️ An extraordinary archaeological find in Kenya could rewrite human history
➡️ The Future Of Innovation Is Skills Driven And Inclusive
➡️ Driving licence: this new update will delight every driver, including seniors
The “unfriendly” oxidative environment inside these red blood cells makes life harder for Plasmodium falciparum at every step of its replication cycle.
Once a mosquito injects parasites into the bloodstream, Plasmodium eventually moves inside red blood cells. There, it feeds on haemoglobin and hijacks the cell’s machinery to multiply. The parasite is finely tuned to the normal biochemical balance of the host cell.
In carriers of the CCND3 variant, that balance is off. The extra oxidative stress disrupts key parasite processes and slows its growth. Experiments show a clear reduction in parasite replication inside these altered red blood cells, even though the parasite can still enter them.
Protection, in this case, is not a locked door that keeps malaria out. It is a booby-trapped room: the parasite gets inside, but conditions are hostile enough to limit its success.
A new chapter in the evolutionary story of malaria resistance
Malaria resistance linked to human genes is not new. Classic examples include:
- Sickle cell trait, which changes the shape and behaviour of red blood cells
- G6PD deficiency, which alters the handling of oxidative stress in those cells
- Certain forms of thalassaemia, which modify haemoglobin production
These variants show how evolution can favour traits that offer some malaria protection, even when they carry health costs, such as anaemia or, in severe forms, life-threatening complications.
The Sardinian CCND3 variant fits the same broad narrative but uses a different route. It nudges red blood cell production and stress levels rather than directly crippling a key enzyme or reshaping the cell dramatically.
The mechanism echoes aspects of G6PD deficiency, where higher vulnerability of red blood cells to oxidative stress harms the parasite. Yet the CCND3 variant acts earlier, by subtly altering how red blood cells are formed. It does not stem from a classic enzyme defect.
Different genes, different pathways, same result: red blood cells that are just uncomfortable enough to keep malaria in check.
Genetic analyses suggest the CCND3 variant rose in frequency over the last few thousand years in Sardinia. Even a modest improvement in survival or fertility under heavy malaria pressure would be enough to tilt the evolutionary scales and spread the variant through local communities.
Turning natural adaptation into new treatments
The most tantalising aspect of the study lies in its medical implications. If a controlled reduction in CCND3 expression can slow malaria inside red blood cells without harming overall health, then drugs might be designed to mimic this effect temporarily.
Crucially, that would mean targeting human cells rather than the parasite itself. Current malaria medicines mostly attack Plasmodium directly. Over time, the parasite often evolves resistance by mutating its own proteins. Host-directed therapies could sidestep that problem.
By reshaping the red blood cell’s internal environment, future drugs could make the human body a less welcoming host, leaving the parasite fewer escape routes.
Researchers stress the need for caution. Cyclin D3 does not only affect red blood cells; it is a key regulator of cell division. Any drug that tampers with this pathway risks unintended effects on other tissues, including those where uncontrolled cell growth links directly to cancer.
The Sardinian variant offers reassurance that moderate changes in CCND3 activity can be tolerated. Carriers typically show normal blood counts and no obvious disease linked to this gene. That real-world “experiment” by nature provides a safety benchmark for potential therapies.
What scientists need to figure out next
From genetics to a practical pill
Turning a genetic insight into a medicine remains a long process. Several key questions stand out:
- How much CCND3 activity must be reduced to slow the parasite without harming blood cell production?
- Can drugs be directed mainly to red blood cell precursors, sparing other dividing cells?
- Would such a treatment work against different strains of Plasmodium falciparum circulating in Africa and Asia?
- Could combining a host-targeted approach with standard antimalarials delay drug resistance further?
Answering these points will likely require a combination of cell culture work, animal models and, eventually, careful human trials in malaria-endemic countries.
How this fits with vaccines and existing tools
The study arrives at a time when malaria control is at a crossroads. Bed nets, insecticides and current drugs have saved millions of lives, yet progress has stalled. Resistance in both mosquitoes and parasites threatens several tools, while climate change may widen malaria’s geographic reach.
New vaccines, such as RTS,S and R21, provide partial protection, especially in young children, but they do not wipe out transmission. Host-based drugs inspired by the Sardinian gene variant would not replace vaccines or nets. They would add another layer of defence.
| Strategy | Main target | Key role |
|---|---|---|
| Insecticide-treated nets | Mosquito | Reduce bites and transmission |
| Standard antimalarial drugs | Parasite | Clear infection from the blood |
| Vaccines | Human immune response | Lower risk of severe disease |
| CCND3-inspired therapies | Red blood cell environment | Limit parasite growth inside cells |
Used together, these methods could form a more resilient strategy, making it harder for malaria to adapt on multiple fronts at once.
Making sense of some key terms
For readers less familiar with the jargon, a few concepts from the study are worth unpacking.
Oxidative stress refers to an imbalance between reactive oxygen species and the body’s ability to neutralise them. High levels can damage cells. In the case of malaria, a controlled increase inside red blood cells can hurt the parasite more than the host, tipping the scales in favour of the patient.
Natural selection describes the process by which genetic traits that slightly improve survival or reproduction become more common across generations. In a malaria-heavy environment, even a small reduction in the chances of dying from the disease can give a variant like the CCND3 change a long-term edge.
Host-directed therapy means treating the human body rather than the invading organism. Instead of killing the parasite outright, these approaches alter the conditions in which it lives so that it struggles to thrive.
What this could mean for people at risk
If future drugs manage to copy the Sardinian gene’s protective effect, they could be used in several ways. People at highest risk during peak transmission seasons, such as young children and pregnant women in endemic regions, might take short courses to reduce the severity of infection. Travellers could receive them as part of their protective regimen.
There are risks to weigh. Any change to red blood cell production could, in theory, worsen anaemia in vulnerable patients, especially where malnutrition or other infections are common. Careful dosing and monitoring would be needed, and such drugs might be unsuitable for everyone.
Still, the idea that a small, local genetic quirk on a Mediterranean island might reshape global thinking on malaria gives researchers fresh energy. As they pick apart CCND3’s role in red blood cell biology, the next generation of antimalarial tools may end up looking as much at human evolution as at the parasite that has shadowed it for millennia.
Originally posted 2026-03-03 14:46:58.